

White Blood Cell Count in Colorectal Cancer Patients, a retrospective study in KHMC

*Haitham Rbaih MD**, *Hala Alsukhni MD***, *Abdullah Abu Anzeh MD**, *Ruba shannaq MD****, *Tania Ojailat MD***

ABSTRACT

Objectives: To assess white blood cell count (WBC) in colorectal cancer (CRC) patients in King Hussein Medical Center and determine if there is an association between high WBC count as an inflammatory marker and CRC and to find any difference in the pattern of the disease in CRC patients who have leukocytosis.

Methods: A retrospective study will be conducted on CRC patients in colorectal surgery department at KHMC over the period from May 2014 to January 2018 with a total number of patients 247. We will refer to these patients' records in Princess Iman Center for Research and Laboratory Sciences to find their WBC count at presentation before surgery, then we will analyze the data to determine if there is any association between high WBC count and CRC and if there is a common findings among these patients.

Results: 247 patients with CRC were studied, the age range was 19-85 years, 123 of the patients were males and 124 were females with a male to female ratio of almost 1:1. WBC count ranged from $3.6 \times 10^3/\mu\text{L}$ to $21.2 \times 10^3/\mu\text{L}$. 43 patients had high WBC count (leukocytosis) which constitutes about 17.4% of all patients. 22 of these 43 patients were males (51%) and 21 were females (49%).

Conclusion: CRC is sometimes associated with increased WBC count, and this may affect the pattern of the disease in patients who have leukocytosis, further comprehensive studies are needed to confirm the effect of leukocytosis on prognosis and the role of WBC as an early screening marker for CRC patient.

Key words: Colorectal cancer, White blood cell, leukocytosis, an inflammatory marker.

RMS April 2023; 30 (1): 10.12816/0061490

Introduction

Colorectal cancer is the third most common cancer in males and females in United States and western countries.^(1,2) The incidence of CRC is increasing gradually with many factors affecting its incidence; mainly the family history of CRC, cigarette smoking, obesity, animal fats, alcohol intake, and sedentary lifestyle.⁽³⁾ Chronic inflammation has been hypothesized to have a role in cancer pathogenesis.^(3,4,5,6) CRCs are classified by etiology as inherited, inflammatory, and sporadic. The most common type is sporadic accounting for more than 80% of CRC.⁽⁷⁾

From the department:

* Surgery, King Hussein Medical Center (KHMC), Amman-Jordan.

** hematology, Princess Iman Research and Laboratory Center, KHMC).

*** histopathology, Princess Iman Research and Laboratory Center, KHMC)

Submission date: 18 September 2019, Acceptance date: 19 December 2019, Publication date: April 2023

It mainly occurs in the middle to late years of life with the mean age at diagnosis of 68 years.^(8,9) Clinical findings in CRC patients depend on the site and size of the tumor and the presence of complications including obstruction, perforation, and hemorrhage. Diagnosis is made through laboratory tests, imaging studies, and lower endoscopic procedures.⁽¹⁰⁾ Screening for CRC aims to detect the disease in the early stages in which the disease is curable and has a favorable prognosis.^(1,8) Screening starts with simple commonly used test which is fecal occult blood (guaiac test), if it shows positive results on two different samples then we proceed to structural screening.⁽⁹⁾ Structural screening for CRC includes flexible sigmoidoscopy and colonoscopy.⁽¹⁾ Tumor markers which are serum proteins may help in screening for CRC but lack of sensitivity and specificity limits their use in screening, the most familiar marker is a carcinoembryonic antigen (CEA) which is more applicable as a prognostic marker and recurrence marker after surgery.^(10,11) Sometimes inflammatory markers used in the screening process of CRC because as we mentioned previously that there is a relationship between inflammatory conditions and cancers.⁽⁵⁾ Chronic inflammation leads to chronic activation of the immune system and antigenic stimulation which play a role in the development of cancer. Inflammatory bowel disease is a well-established cause of CRC.^(3,12) In inflammatory conditions some markers are elevated in the blood such as C-reactive protein (CRP) and white blood cell count (WBC).^(3,4) CRP is a protein produced by the liver in the inflammatory conditions.⁽¹³⁾ WBC count is the circulating leukocytes that increase reactively in many conditions and considered a non-specific inflammatory marker.^(3,4)

In this study, we are trying to find if there is an association between high WBC count and CRC in KHMC.

Method

In this retrospective study, we referred to colorectal surgery department records in KHMC looking for patients diagnosed with colorectal cancer over the period from May 2014 to January 2018, the total number of patients was 247, they were primarily diagnosed with CRC by tissue biopsy through colonoscopy or recto-sigmoidoscopy, and they all underwent surgical resection of the tumor with different open and laparoscopic procedures, histopathological types and grades were documented in lab reports for each patient. Then we referred to patients' records in the laboratory to find their WBC count in the complete blood counts test (CBC) at presentation. Data analysis for these patients was performed to determine mainly the percentage of patients having high WBC count at presentation, and to find if there is any effect of their higher count on the disease outcome and if they have a difference in the Body Mass Index from other patients.

The cut-off point for normal WBC count is $11 \times 10^3/\mu\text{L}$ and the normal range for BMI is 18.5-24.9 kg/m^2 , 25-29.9 kg/m^2 is overweight and above 30 kg/m^2 is obese.^(14,15)

Results

A total number of 247 patients with CRC were studied. The age range was 17-90 years with a median age of 54 years, and the mean age of diagnosis is 58 years. About 91% of patients are above the age of 40 years. The M: F was almost 1:1 with 124 female patients and 123 male patients. The WBC count in their CBC test at presentation was ranging from 3.6-21.2x10³/μL. Patients having high WBC count were 43 out of 247 (17.4%) with 22 of these patients being males (51%) and 21 females (49%). The age range of the patients who were found to have high WBC counts was 40-78 years. For the studied patients the body mass index ranges from 19 to 49 kg/m², with the median BMI=34 kg/m², 41% of patients have normal BMI, 38% have high BMI, and 21% are obese with very high BMI. The targeted patients who have high WBC count was found to have higher BMI with 36% having normal BMI, 28% with high BMI, and 36% obese. The site of tumors in our patients was colonic in 60% and rectal in 40%. In patients with leukocytosis, the percentages differ and showed mainly colonic sites in 77% and rectal in 23%. The patients with high WBC counts do not show differences from other patients with normal counts regarding the type of surgery (open versus laparoscopic) duration of operation, hospital stay, oral intake post-op, complications after surgery, and readmission.

Table I: Characteristics of CRC patients with normal vs. high WBC

	Patients with normal WBC	Patients with high WBC
Age	17-90 years	40-78 years
Sex	M: F=1:1	M: F=1:1
BMI		
Normal	42%	36%
Overweight	40%	28%
Obese	18%	36%
Site of tumor		
Colon	56%	77%
Rectum	44%	23%

Discussion

CRC was reported in some studies to be slightly more common in males with M: F=1.4:1.⁽¹⁶⁾ In our study the incidence of CRC is almost the same in males and females, which is in concordance with Haggaret *al.*⁽¹⁷⁾ In previous studies conducted on Jordanian patients the M: F was found to be 1.3:1 which means that the disease incidence is increasing in females in Jordan.^(18,19) Regarding the age of patients 9% of our patients are below 40 years at the time of diagnosis while in Iran a study conducted in 2005 on CRC patients revealed that about 17% of the patients were younger than 40 years while other studies suggested that 7% of their patients were younger than 40 years.^(20,21) The mean age of diagnosis of CRC in our study group was 58 years while in US according to Surveillance, Epidemiology, and End Results(SEER) national cancer registry database the mean age CRC patients was 71 years which means that CRC presents at a younger age in Jordan as our study and other previous studies on CRC patients in Jordan revealed.^(18,19,22)

In this study, we found that about 17.4% of patients with CRC have leukocytosis at their presentation, and upon analysis of the data of this group of patients we found that there are no differences in their operative and postoperative findings and complications but they were found to have older age range and higher BMI in comparison to the other group. These findings was also reported by Young Jae-Lee *et al.*⁽³⁾

We analyzed the BMI of the patients and found that 41% of them have normal BMI, 38% have high BMI (overweight), and 21% have very high BMI (obese), these BMI results was much lower than that found in North America by the National Surgical Adjuvant Breast and Bowel Project (NSABP).⁽²³⁾ In the targeted group who have leukocytosis the percentage of obese patients was higher than those who do not have leukocytosis, this may result from the possible association between obesity and reactive leukocytosis.⁽²⁴⁾ The explanation for this interrelation between obesity and leukocytosis is that adipocytes release proinflammatory cytokines particularly IL-6 which cause increase in WBC count.⁽²⁾ Regarding the site of tumor, our results was close to D.P.S.Sohalet *al.* who found that about 65% of patients have colonic tumor and 35% have rectal tumor.⁽²⁵⁾ Leukocytosis in cancer patients usually is due to either infection or bone marrow metastasis, but in CRC, leukocytosis is also linked to inflammation in the large bowel that predispose to cancer.^(3,12,26) In Salvenet *al.* leukocytosis in cancer patients was attributed to vascular endothelial growth factor (VEGF) which was produced by human tumor cells, while in other studies the WBC count was linked to increased risk of cancer.^(27,28) A study conducted in Korea demonstrate that high WBC count is associated with increased the incidence and mortality of colon cancer.⁽³⁾ Leukocytosis was linked to increased mortality because of its association with significantly increased risk of venous thromboembolism in cancer patients.⁽²⁹⁾

Limitations of the study

We faced some limitations in our study. First, there was no documented history of the risk factors for CRC that patients have such as colorectal polyps and inflammatory bowel disease. Second, we could not find the WBC count in our patient's records for the previous months before the diagnosis of cancer and for the next months after surgery as a follow-up, so it was not possible to determine the chronicity.

Conclusion

CRC sometimes associated with increased WBC count, and this may affect the pattern of the disease in patients who have leukocytosis, further comprehensive studies are needed to confirm the effect of leukocytosis on prognosis and the role of WBC as an early screening marker for CRC patient.

References:

1. Burt R, Barthel J, Dunn K, David D, Drelichman E, Ford J, *et al.* Colorectal Cancer Screening. Journal of the National Comprehensive Cancer Network 2010 January; 8(1).
2. Poullis A, Foster R, Shetty A, Fagerhol M, Mendall M. Bowel Inflammation as Measured by Fecal Calprotectin: A Link between lifestyle Factors and Colorectal Risk. Cancer Epidemiology, Biomarkers & prevention 2004 February;13(2):279-284.
3. Lee YJ, Lee HR, Nam CM, Hwang UK, Jee SH. White Blood Cell Count and the Risk of Colon Cancer. Yonsei Medical Journal 2006; 47(5):646-656.
4. Erlinger T, Muntner P, Helzlsouer K. WBC Count and the Risk of Cancer Mortality in a National Sample of U.S. Adults: Results from the Second National Health and Nutrition Examination Survey Mortality Study. Cancer Epidemiology, Biomarkers & prevention 2004 June;13(6):1052-1056.
5. Shankar A, Wang JJ, Rochtchina E, Yu MC, Kefford R, Mitchell P. Association Between Circulating White Blood Cell Count and Cancer Mortality. Arch Intern Med 2006 January 23;166:188-194.
6. Chen R, Rabinovitch PS, Crispin DA, Emond MJ, Bronner MP, Brentnall TA. The initiation of colon cancer in a chronic inflammatory setting. Carcinogenesis 2005 April 28; 26(9): 1513-1519.
7. Yang L, Pei Z. Bacteria, inflammation, and colon cancer. World Journal of Gastroenterology 2006 November 14; 12(42): 6741-6746.
8. Levin B. Colorectal Cancer Screening. Cancer Supplement 1993 August 1; 72(3): 1056-1060.
9. Labianca R, Beretta GD, Mosconi S, Milesi L, Pessi MA. Colorectal cancer: screening. Annals of Oncology 2005; 16(2): ii127-ii132.
10. Way LW, Doherty GM. Current Surgical Diagnosis and Treatment. 11th ed. McGraw-Hill; 2003.
11. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brunner N, Chan DW, *et al.* National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancer. Clinical chemistry 2008; 54(12): e11-e79.
12. Byrne KJ, Dalglish AG. Chronic immune activation and inflammation as the cause of malignancy. British Journal of Cancer 2001; 85(4): 473-483.
13. Toriola AT, Cheng TY, Neuhaus ML, Wener MH, Zheng Y, Brown E, *et al.* Biomarkers of inflammation are associated with colorectal cancer risk in women but are not suitable as early detection markers. Int J Cancer. 2013 June 1; 132(11): 2648–2658.
14. McPherson RA, Pincus MR. Henry's clinical Diagnosis and Management by Laboratory Methods. 21st ed. Saunders Elsevier; 2006.
15. American Cancer Society. <https://www.cancer.org/cancer/cancer-causes/diet-physical-activity/body-weight-and-cancer-risk/adult-bmi.html>
16. Maladinov-Mikov M, Dugandzija D, Stabuc B, Muzikravic L. Colorectal Cancer: Current Data on epidemiology, Screening and Follow-up. Archive 2010 September; 18 (1): 11-12.
17. Haggard F, Boushey RP. Colorectal Cancer Epidemiology: Incidence, Mortality, Survival, and Risk Factors. Clinics in Colon and Rectal Surgery 2009; 22(4): 191-197.
18. Dajani YF, Zayid I, Malatjalian DA, Kamal MF. Colorectal Cancer in Jordan and Nova Scotia A Comparative Epidemiologic and Histopathologic Study. Cancer 1980 July 15; 46(2): 420-426.
19. Sharkas G, Arqoub K, Khader Y, Tarawneh M, Nimri O, Al-zaghal M, *et al.* Colorectal Cancer in Jordan: Survival Rate and Its Related Factors. Hindawi Journal of Oncology [Internet]. vol. 2017, Article ID 3180762, 6 pages, 2017. Available from: <https://doi.org/10.1155/2017/3180762>.

20. Ansari R, Mahadayinia M, Sadjadi A, Nourraie M, Kamangar F, Bishehsari F, *et al.* Incidence and age distribution of colorectal cancer in Iran: Results of a population-based cancer registry. *Elsevier journal* 2006; 240 (1): 143-147.
21. Dozois E, Boardman L, Suwanthanma W, Limburg PJ, Cima RR, Bakkan JL, *et al.* Young-Onset Colorectal Cancer in Patients With No Known Genetic Predisposition: Can We Increase Early Recognition and Improve Outcome?. 2008 September; 87(5): 259-263.
22. Ries LAG, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, *et al.* SEER statistics review 1975-2004. Bethesda MD: National Cancer Institute; <http://seer.cancer.gov/csr/1975> 2004.
23. Dignam JJ, Polite BN, Yothers G, Raich P, Colongelo L, Connell MJ, *et al.* Body Mass Index and Outcomes in Patients Who Receive Adjuvant Chemotherapy for Colon Cancer. *Journal of the National Cancer Institute* 2006 November 15; 98(22): 1647-1654.
24. Herishanu Y, Rogowski O, Polliack A, Marilus R. leukocytosis in obese individuals: possible link in patients with unexplained persistent neutrophilia. *European Journal Of hematology* 2006 June; 76(6): 516-520.
25. Sohal DPS, Kuderer NM, Shepherd FA, Pabinger I, Agnelli G, Liebman H, *et al.* Clinical Predictors of Early Mortality in Colorectal Cancer Patients Undergoing Chemotherapy: Results From a Global Prospective Cohort Study. *JNCI J Natl Cancer Inst* 2017; 1(1):1-6.
26. Kasuga I, Makino S, Kiyokawa H, Katoh H, Ebihara Y, Ohyashiki K. Tumor-Related Leukocytosis Is Linked with Poor Prognosis in Patients with Lung Carcinoma. *CANCER* 2001 November 1; 92(9): 2399-2405.
27. Salven P, Orpana A, Joensuu H. Leukocytes and Platelets of Patients with Cancer Contain High Levels of Vascular Endothelial Growth Factor. *Clinical Cancer Research* 1999 March; 5: 487-491.
28. Margolis K, Rodabough RJ, Thomson CA, Lopez AM, McTiernan A. Prospective Study of Leukocyte Count as a Predictor of Incident Breast, Colorectal, Endometrial, and Lung Cancer and Mortality in Postmenopausal Women. *Arch Intern Med.* 2007; 167(17): 1837-1844.
29. Connolly GC, Khoran AA, Kuderer NM, Culakova E, Francis CW, Lyman GH. Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy. *Thromb Res.* 2010 August; 126(2): 113-118.